23 of 50
Johnson & Johnson
Johnson & Johnson
23
Top 50 rank: 23*
Rank in Pharmaceuticals: 4
(Previous rank: 5)
Overall score: 6.21
Ticker:JNJ

Why it's admired:
Stock prices for the world's largest seller of healthcare products—the behemoth behind trusted classics like Band-Aids, Neutrogena, and Listerine— reached record highs, jumping 7% in 2012. And that's despite the continued fall-out from a string of drug marketing issues and product recalls, most notably that of an artificial hip product that has put the company at the center of nearly 11,000 lawsuits and a Justice Department investigation. In 2012, the company was boosted by its acquisition of medical device maker Synthes, strong pharmaceutical sales, and its push into emerging markets. Johnson & Johnson's CEO Alex Gorsky has also stated his intention to keep the company more tightly focused on growth industries and market-leading businesses. —EF

Headquarters:
New Brunswick, NJ
Website: www.jnj.com
Nine key attributes of reputation
Industry rank
Innovation
10
People management
3
Use of corporate assets
2
Social responsibility
1
Quality of management
6
Financial soundness
1
Long-term investment
1
Quality of products/services
11
Global competitiveness
4
From the March 18, 2013, issue.

Notes:
* Tied

What do you think of Johnson & Johnson?
Tech stars

Which technology firms have the best reputations? These companies are the envy of their peers everywhere.

The Most Admired list is the definitive report card on corporate reputations. Our survey partners at Hay Group started with approximately 1,400 companies: the Fortune 1,000—the 1,000 largest U.S. companies ranked by revenue—and non-U.S. companies in Fortune's global 500 database with revenue of $10 billion or more... More
Current Issue
  • Give the gift of Fortune
  • Get the Fortune app
  • Subscribe
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer LIBOR Warning: Neither BBA Enterprises Limited, nor the BBA LIBOR Contributor Banks, nor Reuters, can be held liable for any irregularity or inaccuracy of BBA LIBOR. Disclaimer. Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.